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Short title: Variations in ERCP among pancreatic cancer 
 
 
Abstract 
 
Background : Pancreatic cancer is projected to become the second leading cause of 
cancer-related deaths by 2030. Endoscopic retrograde cholangiopancreatography 
(ERCP) is recommended as first-line therapy for biliary decompression in pancreatic 
cancer. Our study’s aim was to characterize geographic and racial/ethnic disparities in 
ERCP utilization among patients with pancreatic cancer.  
 
Methods: Retrospective cohort study using the U.S. Surveillance, Epidemiology, and 
End Results (SEER)-Medicare database to identify patients diagnosed with pancreatic 
cancer from 2003-2013. The primary outcome was receipt of ERCP, with or without 
stent placement, versus any non-ERCP biliary intervention.  
 
Results: Of 36,619 patients with pancreatic cancer, 37.5% (n=13,719) underwent an 
ERCP, percutaneous drainage, or surgical biliary bypass. The most common biliary 
intervention (82.6%) was ERCP. After adjusting for tumor location and stage, Blacks 
were significantly less likely to receive ERCP than Whites (aOR 0.84, 95% CI 0.72, 
0.97) and more likely to receive percutaneous transhepatic biliary drainage (PTBD) 
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(aOR 1.38, 95% CI 1.14, 1.66). Patients in the Southeast and the West were more likely 
to receive ERCP than those in the Northeast (Southeast aOR 1.21, 95% CI 1.04, 1.40; 
West aOR 1.16, 95% CI 1.01,1.32).  
  
Conclusion: Racial/ethnic and geographic disparities in access to biliary interventions 
including ERCP exist for patients with pancreatic cancer in the US. Our results highlight 
the need for further research and policies to improve access to appropriate biliary 
intervention for all patients. 
 
 
 
Keywords: obstructive jaundice, pancreatic cancer, disparities, ERCP 
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Introduction 
Pancreatic cancer is one of the deadliest malignant neoplasms, with a five-year survival 
of only 7%.1 The incidence of pancreatic cancer has increased over the past decade, 
and it is projected to become the second leading cause of cancer-related deaths by 
2030 in the United States.2,3 The poor prognosis of pancreatic cancer can be attributed 
in part to the large proportion of patients that present at an advanced stage which 
precludes surgical resection.  
 
Biliary decompression is often required in advanced pancreatic cancer for symptomatic 
relief and to allow neoadjuvant chemotherapy in patients with borderline resectable 
tumors.4,5 Endoscopic retrograde cholangiopancreatography (ERCP) plays a critical role 
in the management of obstructive jaundice among pancreatic cancer patients. When 
compared to other biliary decompression interventions, such as percutaneous 
transhepatic biliary drainage (PTBD) or surgical biliary bypass (SBB), ERCP is 
associated with fewer adverse events, shorter length of stay, decreased hospital costs, 
and improved quality of life scores.6,7 Studies appraising the utilization of biliary 
decompression interventions can inform strategies to increase ERCP access and 
appropriate utilization.     
 
Despite the importance of ERCP in the treatment of pancreatic cancer, it remains 
unknown whether racial/ethnic or regional disparities exist for the use of ERCP. These 
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disparities have been described in access to other pancreatic cancer treatments. Black 
patients are less likely than Whites to be referred for curative surgery or chemotherapy, 
even after adjusting for tumor stage.8-12 Furthermore, patients with early stage 
pancreatic cancer in the Northeast are more likely to be referred for surgical resection 
than those in the Southeast, Midwest, and Pacific West.9 Given the findings from prior 
studies, we hypothesized that there are racial/ethnic and geographic disparities in 
access to biliary interventions, including ERCP, such as Black patients being less likely 
to receive ERCP as an initial biliary intervention. Our study’s aim was to characterize 
geographic and racial/ethnic disparities in ERCP utilization among patients with 
pancreatic cancer.  
Methods 
Data Sources 
We conducted a retrospective cohort study using the Surveillance, Epidemiology, and 
End Results (SEER)-Medicare database. The SEER-Medicare database contains data 
on patient demographics, clinical characteristics, tumor location and staging, diagnostic 
and therapeutic treatments, and overall survival for all included patients.13 The SEER 
program collects data from 17 cancer registries and represents roughly 27% of the 
population of the United States, while the Medicare database contains health insurance 
claims for approximately 97% of the population that is 65 years or older.13 Institutional 
Review Board (IRB) exemption was obtained to review previously collected data 
(HUM00128282).  
 
Study Sample  
We included patients diagnosed with pancreatic cancer from 2003-2013. Pancreatic 
cancer histology was based on the International Classification of Diseases for Oncology 
(ICD-O-3) codes (Supplemental Table 1). Biliary interventions evaluated in our study 
included ERCP, PTBD, and SBB. Patients were excluded if they had a history of other 
cancer, histology other than adenocarcinoma, or if their pancreatic cancer diagnosis 
was made at time of death or on autopsy (Supplemental Figure 1). We excluded 
patients with multiple biliary interventions on the same date due to unclear order of 
procedures and concerns for coding errors since this is unlikely to happen in clinical 
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practice. Patients with biliary interventions greater than 2 months before their diagnosis 
were also excluded given this was more likely related to reasons other than pancreatic 
cancer. We evaluated patient enrollment in non-health maintenance organizations 
(HMOs), Medicare Part A and Medicare Part B. Patients were required to have 
continuous enrollment in Medicare Part A and B coverage, without concomitant 
enrollment in an HMO, for at least two months prior to their pancreatic cancer diagnosis 
and up to 12 months after their diagnosis or to death. This was because some of their 
claims may be captured by HMOs rather than by Medicare. (Supplemental Figure 1). 
The MEDPAR and outpatient files were used to identify diagnosis and procedural codes 
using International Classification of Diseases (ICD)-9 codes, the American Medical 
Association Common Procedure Terminology (CPT) codes, and the health care 
common procedures codes (HCPCS) (Supplemental Table 1).9,11,14-16 
 
Study Variables 
All variables used in the study were available in SEER-Medicare. Sex and race/ethnicity 
were obtained from the SEER file. Race/ethnicity, based on SEER designation, was 
classified as White, Black, Asian, Hispanic, Native American, other, or unknown. Patient 
age was based on the Medicare birth month, day, and year. The age was calculated as 
the age at the date of diagnosis. Date of diagnosis was based on SEER designated 
date of pancreatic cancer diagnosis. The SEER designated date of diagnosis has been 
shown to have a nearly 90% agreement with the first Medicare claim with a cancer 
diagnosis.17 Charlson comorbidity index (CCI) was calculated using the MEDPAR and 
outpatient claims one year prior to their pancreatic cancer diagnosis.  
 
Tumor stage was defined using American Joint Committee of Cancer (AJCC) staging, 
6th edition. However, AJCC staging was available in SEER-Medicare from 2004 to 
present. Tumor stage for patients diagnosed in 2003 was considered missing for 
purposes of our analysis. Location of pancreatic tumor, based on the SEER primary 
site, was designated as head of pancreas, body/tail of pancreas, or unknown.  
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SEER regions were divided into Northeast (Connecticut and New Jersey), Southeast 
(Atlanta, greater Georgia, rural Georgia, Kentucky, and Louisiana), Midwest (Detroit and 
Iowa), and the West (San Francisco, Los Angeles, San Jose, greater California, New 
Mexico, Seattle, Utah, and Hawaii).18. 
 
Clinical characteristics were also obtained from SEER-Medicare. From the MEDPAR 
files, we were able to determine whether a patient required ICU level care in either the 
general, medical, or surgical ICU and the date of the admission to the ICU. Patients 
were determined to require ICU level care if the admission date was after the time of 
their diagnosis (if no biliary intervention was performed) or at/after the time of their 
biliary intervention. ICD-9 codes from the MEDPAR files were used to identify patients 
with jaundice, cholangitis, or gastric outlet obstruction during any admission after the 
time of their diagnosis but prior to a biliary intervention, if they received one. SEER has 
recorded whether patients have received site-specific surgery with classifications to the 
type of surgery they received, including a Whipple.  Patients were considered to have 
received a Whipple procedure based on this SEER designation of receiving site specific 
surgery. However, the date of this procedure was not recorded in the SEER file. Last, 
ICD-9 codes and CPT codes were used to identify if a patient received an ERCP, 
PTBD, or SBB and the date of their procedure.  
 
Outcomes 
Our primary outcome was receipt of ERCP, with or without stent placement, versus a 
non-ERCP biliary intervention (i.e. PTBD or SBB). Patients without any biliary 
decompression were excluded. We also excluded patients with Whipple resection 
because we could not accurately determine if the biliary intervention preceded or post-
dated the surgery.  
 
We included any biliary intervention that occurred within two months prior to pancreatic 
cancer diagnosis or anytime after diagnosis because: a) biliary decompression can be 
achieved prior or concurrent to confirming a diagnosis of pancreatic cancer and b) 
pancreatic cancer codes may be delayed after a diagnosis has been confirmed.19 A two-
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month window was determined a priori based on expert opinion; the appropriateness of 
this cut-off was confirmed as there was a step-up in the frequency of biliary 
interventions two months prior to diagnosis of pancreatic cancer in our dataset.  
 
Statistical Analysis 
We first characterized the proportions of patients who received ERCP, non-ERCP biliary 
drainage, and no intervention. For our analysis, we identified correlates of ERCP receipt 
using Student t test and chi-square test for continuous and categorical variables, 
respectively. The Cochrane-Armitage test for trend was used to evaluate receipt of 
ERCP by year. Stepwise forward regression was used to identify covariates of interest 
which were ultimately used in our multivariable logistic model. The covariates in our 
analysis were: race, gender, age at the time of diagnosis, SEER region, location of 
tumor (head, body, tail of pancreas), AJCC tumor stage, 6th edition (Stage I - Stage IV), 
year of diagnosis (continuous variable), requirement of ICU stay, CCI, and presence of 
cholangitis, gastric outlet obstruction, or jaundice. Analyses were conducted using Stata 
15.0 (Stata Corp, College Station, TX).  
 
Results 
Study Sample and Patient Demographics 
Of 83,164 potentially eligible patients, we excluded patients with a history of other 
cancers (n=17,348), histology other than adenocarcinoma (n=4,065), initial diagnosis of 
pancreatic cancer on death certificate or autopsy (n=2,392), and patients with non-
continuous Part A/B coverage or coverage by an HMO during the study period 
(n=19,522). Of the remaining 39,837 patients, we excluded 837 patients who had no 
Medicare Part A or B claims, 1,752 patients who had a biliary intervention greater than 2 
months prior to their diagnosis, and 629 patients who had more than one procedure on 
the same date. Overall, there were 36,619 eligible patients with pancreatic cancer 
(Supplemental Figure 1).   
 
Demographics of included patients are found in Table 1. Most patients were White and 
between the age of 65 to 80 years old. Nearly half of the patients presented with tumors 
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in the head of the pancreas, and over 40% had stage IV disease at the time of 
diagnosis. Only 11% of patients had jaundice and less than 5% of patients received ICU 
care after pancreatic cancer diagnosis. Among the more than 1400 patients who 
required ICU level care after their diagnosis, the majority (58%) received a biliary 
intervention (Table 1).  
 
In total, 13,719 patients underwent a biliary decompressive intervention. The most 
common biliary decompressive intervention in this cohort was ERCP (82.6%) (Table 1). 
The remainder of patients underwent PTBD (8.8%) or SBB (8.6%) (Table 1). There was 
a decrease in the overall use of biliary interventions from 2003-2013 (Table 1). The 
majority of patients who underwent a biliary intervention had a mass in the head of the 
pancreas (72.3%) (Table 1). Among the over 13,000 patients who underwent a biliary 
intervention, 30.5% had stage IV disease (Table 1).  
 
Receipt of ERCP as initial biliary intervention 
Compared to patients who had a non-ERCP biliary intervention, a greater proportion of 
patients who underwent an ERCP were White, have a mass in the pancreatic head, 
have early stage cancer, and present with jaundice or cholangitis (Table 2). While the 
use of ERCP decreased from 2003-2013, the use of non-ERCP interventions also 
decreased (Table 2). A fewer proportion of patients who received an ERCP required a 
stay in the ICU as compared to those patients who underwent a non-ERCP intervention 
(Table 2). There was no statistically significant difference in the CCI between patients 
who underwent ERCP versus a non-ERCP intervention (Table 2).  
 
There were racial/ethnic and geographic disparities in receipt of ERCP as the initial 
biliary intervention after adjusting for tumor stage and clinical presentation (Table 3). 
Blacks were significantly less likely to receive an ERCP compared to Whites (aOR 0.84, 
95% CI 0.72, 0.97) (Table 3). However, Blacks were more likely to receive PTBD 
compared to Whites (aOR 1.38, 95% CI 1.14-1.66) (results not shown). Patients in the 
Southeast and the West were more likely to receive ERCP compared to those in the 
Northeast (Table 3).  
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Discussion 
In this analysis of population-based data, we found racial/ethnic and geographic 
disparities in receipt of biliary interventions, including ERCP, among patients with 
pancreatic cancer. Black pancreatic cancer patients were less likely to receive an 
ERCP, which is the preferred route of biliary decompression, and more likely to receive 
PTBD. Patients in the Northeast were less likely to undergo ERCP as compared to 
those in the Southeast and West. These findings highlight the presence of inequitable 
utilization of endoscopic procedures that have been shown to play a critical role in the 
management of pancreatic cancer. 
 
ERCP is recommended as the initial biliary decompressive intervention for patients who 
present with biliary obstruction due to a pancreatic head mass.20 Our results are 
encouraging in that they demonstrate that the large majority (~83%) of patients who 
underwent a biliary intervention due to pancreatic cancer received the optimal treatment 
modality – ERCP. However, our findings also demonstrate that approximately one in six 
pancreatic cancer patients received PTBD or SBB, with Black patients being less likely 
than Whites to receive an ERCP. The primary driver of non-ERCP interventions is 
unclear at this time. While a growing body of literature, including randomized controlled 
trials and ‘real world’ cohort studies, have shown that endoscopic biliary drainage is 
associated with lower adverse events, shorter length of hospitalization, lower costs, and 
better quality of life scores, our study demonstrates that disparities in access to ERCP 
across racial/ethnic and geographic cohorts remain.6,7 Further studies are needed to 
determine if these differences are related to accessibility of treatment, local expertise, or 
regional practice variations in an effort to bridge the gap in care among pancreatic 
cancer patients.  
 
Minority populations have been found to be especially vulnerable to the inequitable 
distribution of healthcare across America.9,21,22 While factors such as tumor biology may 
account for some of the differences in cancer related mortality among minority groups, 
existing literature highlights racial and ethnic disparities in the receipt of cancer 
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treatments, such as Whipple surgery or referrals for chemotherapy.10-12,21 The findings 
from our study add to the growing body of literature highlighting disparate receipt of 
oncological care among Blacks and also highlight that these inequities may exist in the 
delivery of endoscopic procedures important in the care of pancreatic cancer patients. 
While differences in access to ERCP may play a central role in these disparities, 
examining other factors, such as patient preferences, physician preferences, or local 
expertise are important next steps to understanding the findings from our study.  
 
We also noted regional variations in receipt of ERCP across the United States. Prior 
studies evaluating receipt of surgery for early-stage pancreatic cancer found patients in 
the Northeast were more likely to be referred for curative surgery, possibly due in part to 
the concentration of high volume, tertiary care centers in the Northeast that specialize in 
hepato-pancreato-biliary surgery.9 In our study, we found patients in the Northeast were 
less likely to receive an ERCP as compared to non-ERCP biliary interventions if 
decompression was required. Regional variations in expertise and care could be 
potential explanations. For example, since patients in the Northeast are more likely to 
undergo surgery for early-stage pancreatic cancer, those who are deemed unresectable 
in the operating room may be receiving SBB prior to closure, reducing the fraction of 
ERCP treated patients. However, we cannot exclude the possibility of confounding by 
unmeasured factors. Although existing data describe a >90% success rate in selective 
biliary cannulation in pancreatic cancer, and the findings from our study show that over 
85% of patients received an initial ERCP for biliary decompression, our results suggest 
that treatment varies throughout the United States.20 Future research should focus on 
how those disparities may influence clinical outcomes and how access or local expertise 
in care may change the procedure a patient receives. 
 
Interestingly, almost 45% of our patient population underwent a biliary decompressive 
intervention although only 11% of patients had an ICD-9 code for jaundice. This could 
be due to miscoding or lack of coding for jaundice. Given that the vast majority of 
ERCPs are performed in a hospital based setting, as opposed to an ambulatory surgical 
center, the decision was made to use the MEDPAR and outpatient claims files only, 
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rather than including claims from carrier claims files as well. This also prevented double 
counting of outpatient procedures that may be listed in both the outpatient claims file 
and carrier claims files. However, carrier claims files include claims data by non-
institutional providers, such as physician assistants, and this could account for a lower 
than expected percentage of patients with jaundice. 
 
Our study has some important limitations, including those inherent to using insurance 
claims. First, while linkage of SEER data with Medicare claims data increases available 
clinical information, we cannot exclude the possibility of residual confounding in 
multivariable analyses showing racial/ethnic and geographic disparities.13,23 Importantly, 
we were unable to determine necessity for biliary decompression, especially given that 
over 50% of patients did not undergo a biliary intervention, which may have been 
appropriate given lack of symptoms, laboratory abnormalities, or significant 
comorbidities. Second, SEER-Medicare does not include the entire US and is limited to 
only the older population. Third, we cannot exclude the possibility of miscoding for 
important variables such as race/ethnicity, diagnosis, or procedural codes. Last, there 
was a downtrend in the number of ERCPs performed over our study and especially in 
2013. However, this trend has been observed in prior studies evaluating the trend of 
ERCP in the US.24,25  
 
To our knowledge, this is the first population-based study to examine variations in 
access to ERCP across the United States. The findings suggest that utilization of ERCP 
varies according to race/ethnicity and geographic location in the United States. 
Understanding the clinical implications and factors that play a role in these gaps will be 
important to improving quality cancer care for all patients with pancreatic cancer.  
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Table 1: Baseline Characteristics of Patient Cohort 
 
 Total Number (%) Biliary Intervention+  
Total Number 36,619 13,719 (37.5%) 
Biliary Intervention   
ERCP  --- 11,333 (82.6%) 
Percutaneous Drainage --- 1,210 (8.8%) 
Surgical Bypass --- 1,176 (8.6%) 
Gender   
Male 16,376 (44.7%) 6,037 (44.0%) 
Female 20,243 (55.3%) 7,682 (56.0%) 
Race   
White 29,365 (80.2%) 10,973 (80.0%) 
Black 4,089 (11.2%) 1,561 (11.4%) 
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Asian 1,308 (3.6%) 476 (3.5%) 
Hispanic 760 (2.1%) 311 (2.3%) 
Native American 139 (0.4%) 47 (0.3%) 
Other 958 (2.6%) 351 (2.6%) 
Year of Diagnosis   
2003 3,319 (9.1%) 1,381 (10.1%) 
2004 3,368 (9.2%) 1,399 (10.2%) 
2005 3,387 (9.3%) 1,331 (9.7%) 
2006 3,491 (9.5%) 1,296 (9.5%) 
2007 3,431 (9.4%) 1,266 (9.2%) 
2008 3,542 (9.7%) 1,293 (9.4%) 
2009 3,425 (9.4%) 1,267 (9.2%) 
2010 3,462 (9.5%) 1,225 (8.9%) 
2011 3,390 (9.3%) 1,214 (8.9%) 
2012 3,279 (9.0%) 1,158 (8.4%) 
2013 2,525 (6.9%) 889 (6.5%) 
Age at Diagnosis    
<65 3,254 (8.9%) 1,027 (7.5%) 
65-69 6,565 (17.9%) 2,514 (18.3%) 
70-79 13,800 (37.7%) 5,305 (38.7%) 
80-89 10,690 (29.2%) 4,112 (30.0%) 
>90 2,310 (6.3%) 761 (5.6%) 
Location of Pancreatic Tumor   
Head of Pancreas 17,658 (48.2%) 9,914 (72.3%) 
Body/Tail 7,949 (21.7%) 856 (6.2%) 
Unknown 11,012 (20.1%) 2,949 (21.5%) 
SEER Demographic   
Northeast 7,825 (21.4%) 2,975 (21.7%) 
Southeast 8,786 (24.0%) 3,325 (24.2%) 
Midwest 4,440 (12.1%) 1,596 (11.6%) 
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West 15,568 (42.5%) 5,823 (42.4%) 
Stage of Disease (AJCC), 6th edition*   
Stage I 2,308 (6.3%) 1,092 (8.0%) 
Stage II 7,257 (19.8%) 3,369 (24.6%) 
Stage III 2,459 (6.7%) 1,252 (9.1%) 
Stage IV 15,509 (42.4%) 4,177 (30.5%) 
Unknown 5,767 (15.8%) 2,448 (17.8%) 
Charlson Comorbidity Index   
0 10,835 (29.6%) 4,103 (29.9%) 
1 7,309 (20.0%) 2,796 (20.4%) 
2 9,647 (26.3%) 3,810 (27.8%) 
Jaundice   
Yes 4,041 (11.0%) 2,937 (21.4%) 
No 32,578 (89.0%) 10,782 (78.6%) 
Cholangitis   
Yes 369 (1.0%) 296 (2.2%) 
No 36,250 (99.0%) 13,423 (97.8%) 
ICU Stay After Diagnosis   
Yes 1,420 (3.9%) 823 (6.0%) 
No 35,199 (96.1%) 12,896 (94.0%) 
Gastric Outlet Obstruction   
Yes 267 (0.7%) 181 (1.3%) 
No 36,325 (99.3%) 13,538 (98.7%) 
*Does not include 2003 diagnoses. 
 
 
 
 
 
 
 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Characteristics of patients with ERCP versus non-ERCP biliary intervention  
 ERCP (n, %) Non-ERCP Intervention (n, 
%) 
p-
value 
Total Number (n=13,719) 11,333 (82.6%) 2,386 (17.4%)  
Gender   0.084 
Male 4,949 (43.7%) 1,088 (45.6%)  
Female 6,384 (56.3%) 1,298 (54.4%)  
Race   0.01 
White 9,135 (80.6%) 1,838 (77.0%)  
Black 1,244 (11.0%) 317 (13.3%)  
Asian 379 (3.3%) 97 (4.1%)  
Hispanic 251 (2.2%) 60 (2.5%)  
Native American 36 (0.3%) 11 (0.5%)  
Other 288 (2.5%) 63 (2.6%)  
Year of Diagnosis   0.68** 
2003 1,081 (9.5%) 300 (12.6%)  
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2004 1,147 (10.1%) 252 (10.6%)  
2005 1,060 (9.4%) 271 (11.4%)  
2006 1,037 (9.2%) 259 (10.9%)  
2007 1,048 (9.3%) 218 (9.1%)  
2008 1,083 (9.6%) 210 (8.8%)  
2009 1,034 (9.1%) 233 (9.8%)  
2010 1,034 (9.1%) 191 (8.0%)  
2011 1,035 (9.1%) 179 (7.5%)  
2012 1,006 (8.9%) 152 (6.4%)  
2013 768 (6.8%) 121 (5.1%)  
Age at Diagnosis    <0.001 
<65 834 (7.4%) 193 (8.1%)  
65-69 2,023 (17.9%) 491 (20.6%)  
70-79 4,348 (38.4%) 957 (40.1%)  
80-89 3,474 (30.7%) 638 (26.7%)  
>90 654 (5.8%) 107 (4.5%)  
Location of Pancreatic Tumor   0.008 
Head of Pancreas 8,245 (72.8%) 1,669 (70.0%)  
Body/Tail 681 (6.0%) 175 (7.3%)  
Unknown 2,407 (21.2%) 542 (22.7%)  
SEER Demographic   0.063 
Northeast 2,425 (21.4%) 550 (23.1%)  
Southeast 2,788 (24.6%) 537 (22.5%)  
Midwest 1,302 (11.5%) 294 (12.3%)  
West 4,818 (24.5%) 1,005 (42.1%)  
Stage of Disease (AJCC), 6th 
edition* 
  <0.001 
Stage I 959 (9.4%) 133 (6.4%)  
Stage II 2,831 (27.6%) 538 (25.8%)  
Stage III 986 (9.6%) 266 (12.8%)  
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Stage IV 3,368 (32.9%) 809 (38.8%)  
Unknown 2,108 (20.6%) 340 (16.3%)  
Charlson Comorbidity Index   0.71 
0 3,402 (38.2%) 701 (38.9%)  
1 2,339 (26.3%) 457 (25.4%)   2 3,166 (35.6%) 644 (35.7%)  
Jaundice   <0.001 
Yes 2,612 (23.1%) 325 (13.6%)  
No 8,721 (77.0%) 2,061 (86.4%)  
Cholangitis   <0.001 
Yes 271 (2.4%) 25 (1.1%)  
No 11,062 (97.6%) 2,361 (99.0%)  
ICU Stay After Diagnosis   <0.001 
Yes 413 (3.6%) 410 (17.2%)  
No 10,920 (96.4%) 1,976 (82.8%)  
Gastric Outlet Obstruction   0.49 
Yes 146 (1.3%) 35 (1.5%)  
No 11,187 (98.7%) 2,351 (98.5%)  
*Does not include 2003 diagnoses.  
** p-value represents test for trend .  
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Table 3: Correlates for receipt of ERCP as initial biliary intervention vs. non-ERCP 
interventions 
 Unadjusted (OR, 95% CI) Adjusted (aOR, 95% CI) 
ERCP   
Race   
White Ref Ref 
Black 0.79 (0.69, 0.90) 0.84 (0.72, 0.97) 
Asian  0.79 (0.63, 0.99) 0.78 (0.61, 1.01) 
Hispanic 0.84 (0.63, 1.12) 0.82 (0.60, 1.12) 
Native American 0.66 (0.33, 1.30) 0.68 (0.33, 1.44) 
Gender   
Male Ref Ref 
Female 1.08 (0.99, 1.18) 1.05 (0.95, 1.16) 
Age at Diagnosis    
<65 Ref Ref 
65-69 0.95 (0.79, 1.15) 0.92 (0.75, 1.12) 
70-79 1.05 (0.89, 1.25) 0.98 (0.82, 1.19) 
80-89 1.26 (1.05, 1.51) 1.08 (0.88, 1.32) 
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>90 1.41 (1.09, 1.83) 1.21 (0.90, 1.61) 
SEER Region   
Northeast Ref Ref 
Southeast 1.18 (1.03, 1.34) 1.21 (1.04, 1.40) 
Midwest 1.00 (0.86, 1.17) 0.99 (0.84, 1.18) 
West 1.09 (0.97, 1.22) 1.16 (1.01, 1.32) 
Location of Tumor   
Head of Pancreas Ref Ref 
Body/Tail 0.79 (0.66, 0.94) 0.89 (0.73, 1.08) 
Stage of Disease (AJCC)*   
Stage I Ref Ref 
Stage II 0.73 (0.60, 0.89) 0.75 (0.61, 0.92) 
Stage III 0.51 (0.41, 0.64) 0.55 (0.44, 0.70) 
Stage IV 0.58 (0.47, 0.70) 0.63 (0.51, 0.78) 
Charlson Comorbidity 
Index 
  
0 Ref --- 
1 1.05 (0.93, 1.20) ---  2 1.01 (0.90, 1.14) --- 
Year of Diagnosis   
Per 1 Year 1.06 (1.03, 1.07) 1.05 (1.03, 1.07) 
Jaundice   
No Ref Ref 
Yes 1.90 (1.68, 2.15) 1.68 (1.47, 1.92) 
Cholangitis  --- 
No Ref --- 
Yes 2.31 (1.53, 3.49) --- 
ICU Stay After Diagnosis   
No Ref Ref 
Yes 0.18 (0.16, 0.21) 0.19 (0.16, 0.22) 
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Gastric Outlet Obstruction  --- 
No Ref --- 
Yes 0.88 (0.60, 1.27) --- 
*Does not include 2003 diagnoses.  
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